Program
lazertinib
Also written as “Lazertinib”, “Lazertinib 240 mg/160 mg” and “YH25448”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Osteoarthritis, Knee, led by 4 companies.
Drug pageLazertinib: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 125 open or running | phase 3since Jul 23, 2020 | Aug 21, 2019 | Feb 12, 2027phase 1 · NCT04077463 |
| Yuhanits history only | 40 open or running | phase 3since Jan 14, 2020 | Jan 26, 2017 | none ahead |
| Abionits history only | 11 open or running | phase 2since Sep 4, 2022 | Sep 4, 2022 | Feb 2029phase 2 · NCT05541822 |
| BUZZZ Pharmaceuticalsits history only | 10 open or running | phase 2since Jul 22, 2021 | Jul 22, 2021 | none ahead |
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseJanssen (Johnson & Johnson) licensed it from Yuhan, for everywhere outside South Korea.Announced Nov 5, 2018 · Source: Yuhan (release), Nov 5, 2018
How Abion and BUZZZ Pharmaceuticals relate to it is not in the registry or these sources.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2017Named lazertinibINNProposed as its International Nonproprietary Name in WHO's List 117 · before, YH25448
- Nov 5, 2018Janssen (Johnson & Johnson) licensed it from YuhanLicenseEverywhere outside South Korea · announced · Yuhan (release)
- Aug 21, 2019First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04075396 · 29 enrolled · United States, Spain, United Kingdom
- Aug 30, 2019Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04077463 · 701 enrolled · United States, China, France and more
- May 28, 20202 phase 1 studies in HealthyNCT04410094, NCT04410081
- Jul 23, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04487080 · 1,074 enrolled · United States, Argentina, Australia and more
- Jul 30, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04988295 · 776 enrolled · United States, Argentina, Belgium and more
- Sep 17, 2021Phase 1 study in HealthyNCT05076877 · 20 enrolled · United States
- Nov 2, 2021Phase 1 study in Hepatic ImpairmentNCT05112952 · 16 enrolled · Germany
- Feb 15, 2023Phase 1 study in HealthyNCT05742594 · 64 enrolled · United States
- Jun 1, 2023Phase 1 study in HealthyNCT05896683 · 72 enrolled · Belgium
- Oct 30, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06667076 · 480 planned · United States, Belgium, Finland and more
- May 8, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07586202 · 68 planned · United States, Canada, China and more
Ahead
- Feb 12, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT04077463
- Mar 2, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07586202
- May 23, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06667076
TargetBeta
“An orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 12 Johnson & Johnson leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07586202Carcinoma, Non-Small-Cell Lung · United States, Canada, China and more | 2 | Recruiting | Mar 2, 2028 | 68 |
| NCT06667076Carcinoma, Non-Small-Cell Lung · United States, Belgium, Finland and more | 2 | Recruiting | May 23, 2029 | 480 |
| NCT05896683Healthy · Belgium | 1 | Completed | Sep 1, 2023 | 72 |
| NCT05742594Healthy · United States | 1 | Completed | Mar 31, 2023 | 64 |
| NCT05112952Hepatic Impairment · Germany | 1 | Completed | Jul 11, 2022 | 16 |
| NCT05076877Healthy · United States | 1 | Completed | Feb 10, 2022 | 20 |
| NCT04988295Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Jul 10, 2023 | 776 |
| NCT04487080Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 11, 2023 | 1,074 |
| NCT04410094Healthy · United States | 1 | Completed | Dec 30, 2020 | 32 |
| NCT04410081Healthy · Netherlands | 1 | Completed | Mar 2, 2021 | 8 |
| NCT04077463Carcinoma, Non-Small-Cell Lung · United States, China, France and more | 1 | Active, not recruiting | Feb 12, 2027 | 701 |
| NCT04075396Carcinoma, Non-Small-Cell Lung · United States, Spain, United Kingdom | 2 | Completed | Jan 8, 2021 | 29 |
How it is read
Names in the registry
- “Lazertinib”, 12 entries
- “Lazertinib 240 mg/160 mg”, 1 entry
- “YH25448”, 1 entry
- “Lazertinib(G001)”, 1 entry
- “Lazertinib(G002)”, 1 entry
Codes read as this program: G001.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Osteoarthritis, Knee, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.